Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer

Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive... BACKGROUNDIn May 2006, the UK Human Fertilization and Embryology Authority (HFEA) approved use of preimplantation genetic diagnosis (PGD) for lower penetrance, late onset cancer susceptibility syndromes such as hereditary breast and ovarian cancer (HBOC). This is the first report on views of BRCA gene mutation carriers on use of PGD for HBOC.METHODSBetween December 2005 and February 2006, a postal survey of BRCA mutation carriers attending a Familial Cancer Clinic was undertaken.RESULTSOf 102 women sent questionnaires, 52 (51) responded. Thirty-nine (75) felt it was acceptable to offer PGD for HBOC. Fifteen (37.5) of 40 who had completed their families would personally have considered PGD if it had been available. Only one of seven (14) contemplating a future pregnancy would consider PGD. Eighteen (35) wrote extensively about their concerns including increasing availability of effective treatment and good quality of life.CONCLUSIONSThe majority of BRCA gene mutation carriers are supportive of offering PGD to others, thus endorsing the HFEA decision. However, most women would not consider it personally. Concerns raised highlight the need for regular HFEA reviews of the licensing criteria, as HBOC may cease to be a serious life threatening illness in the future. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Reproduction Oxford University Press

Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer

Loading next page...
 
/lp/oxford-university-press/views-of-brca-gene-mutation-carriers-on-preimplantation-genetic-L0PkXz2JdC

References (14)

Publisher
Oxford University Press
Copyright
© Published by Oxford University Press.
ISSN
0268-1161
eISSN
1460-2350
DOI
10.1093/humrep/dem055
pmid
17428877
Publisher site
See Article on Publisher Site

Abstract

BACKGROUNDIn May 2006, the UK Human Fertilization and Embryology Authority (HFEA) approved use of preimplantation genetic diagnosis (PGD) for lower penetrance, late onset cancer susceptibility syndromes such as hereditary breast and ovarian cancer (HBOC). This is the first report on views of BRCA gene mutation carriers on use of PGD for HBOC.METHODSBetween December 2005 and February 2006, a postal survey of BRCA mutation carriers attending a Familial Cancer Clinic was undertaken.RESULTSOf 102 women sent questionnaires, 52 (51) responded. Thirty-nine (75) felt it was acceptable to offer PGD for HBOC. Fifteen (37.5) of 40 who had completed their families would personally have considered PGD if it had been available. Only one of seven (14) contemplating a future pregnancy would consider PGD. Eighteen (35) wrote extensively about their concerns including increasing availability of effective treatment and good quality of life.CONCLUSIONSThe majority of BRCA gene mutation carriers are supportive of offering PGD to others, thus endorsing the HFEA decision. However, most women would not consider it personally. Concerns raised highlight the need for regular HFEA reviews of the licensing criteria, as HBOC may cease to be a serious life threatening illness in the future.

Journal

Human ReproductionOxford University Press

Published: Jun 11, 2007

Keywords: Keywords BRCA preimplantation diagnosis reproductive options

There are no references for this article.